Results 31 to 40 of about 112,073 (304)

Relationship between body composition and the histology of non‐alcoholic fatty liver disease: a cross‐sectional study

BMC Gastroenterology, 2021
Background Causes of non-alcoholic fatty liver disease and its progression include visceral fat accumulation and loss of muscle mass; however, which of the two phenomena is more critical is unclear.
Teruki Miyake, Masumi Miyazaki, Osamu Yoshida, Sayaka Kanzaki, Hironobu Nakaguchi, Yoshiko Nakamura, Takao Watanabe, Yasunori Yamamoto, Yohei Koizumi, Yoshio Tokumoto, Masashi Hirooka, Shinya Furukawa, Eiji Takeshita, Teru Kumagi, Yoshio Ikeda, Masanori Abe, Kumiko Toshimitsu, Bunzo Matsuura, Yoichi Hiasa   +18 more
doaj   +1 more source

Non-alcoholic fatty liver disease: a global concern

, 2022
Liver disease is a worldwide issue with death rates exponentially increasing over the last 50 years. Although there are many underlying aetiologies, one of the top three causes of liver disease is non-alcoholic fatty liver disease (NAFLD), which is an ...
Mortimore, G.
core   +1 more source

Treatments for NAFLD [PDF]

Farmacja Polska, 2021
Non-alcoholic fatty liver disease (NAFLD) is categorised into simple steatosis, termed nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
Katarzyna Juszczyńska
doaj   +1 more source

Non‐alcoholic fatty liver disease

Journal of Diabetes, 2012
AbstractNon‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is closely associated with metabolic syndrome. The alarming epidemics of diabetes and obesity have fueled an increasing prevalence of NAFLD, particularly among these high‐risk groups.
Ana C, Tuyama, Charissa Y, Chang
openaire   +2 more sources

Elevated endotoxin levels in non-alcoholic fatty liver disease [PDF]

, 2010
Background: Emerging data indicate that gut-derived endotoxin may contribute to low-grade systemic inflammation in insulin resistant states. This study aimed to examine the importance of serum endotoxin and inflammatory markers in non-alcoholic fatty ...
Ashour, E., Steven J Creely, Youssef-Elabd, E., Youssef-Elabd, Elham M., Harte, A., Abdalla, M., Creely, S., Ashour Esmat, da Silva, Nancy F., McTernan Philip G, Mohga S Abdalla, Day, C.P., Day, Christopher Paul, Billyard, T., Burt, Alastair D., Burt Alastair D, Philip G McTernan, Kumar, S., Elham M Youssef-Elabd, da Silva, N.F., Alison L Harte, Burt, A.D., Nancy F da Silva, Amin, Ashraf I., Tripathi, Gyanendra, Sharada, H., Burt, A., McTernan, P. G., Billyard, Thomas, da Silva, N., Harte, A.L., Day Christopher P, Youssef-Elabd Elham M, Tripathi Gyanendra, Alastair D Burt, Sharada, Hayat M., Hayat M Sharada, Kumar Sudhesh, Abdalla Mohga S, Sharada, H.M., Day, C., Abdalla, Mohga S., Sudhesh Kumar, Creely, S.J., McGee Kirsty C, Esmat Ashour, McTernan, P., Abdalla, M.S., Tripathi, G., McGee, K.C., Youssef-Elabd, E.M., Kirsty C McGee, Christopher P Day, Ashour, Esmat, McGee, K., Billyard Thomas, Gyanendra Tripathi, Thomas Billyard, Kumar, Sudhesh, Amin Ashraf I, Amin, A., da Silva Nancy F, Harte, A. L., Ashraf I Amin, McTernan, P.G., Creely, Steven J., McGee, K. C., Harte Alison L, Creely Steven J, Sharada Hayat M, Amin, A.I.   +70 more
core   +1 more source

Pathophysiology of Non Alcoholic Fatty Liver Disease [PDF]

International Journal of Molecular Sciences, 2016
The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style and inflammation, which have a major impact on the severity of the clinicopathologic outcome of non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of the pathophysiological interplay among major circulating ...
Salvatore Petta, Amalia Gastaldelli, Eleni Rebelos, Elisabetta Bugianesi, Piergiorgio Messa, Luca Miele, Gianluca Svegliati-Baroni, Luca Valenti, Ferruccio Bonino   +8 more
openaire   +3 more sources

Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments

, 2023
Elevated liver enzyme levels are a frequent incidental finding in primary care, and non-alcoholic fatty liver disease is the main cause of incidental elevation of liver enzymes worldwide.
Yeong Yeh Lee, Vincent Tee
core   +1 more source

The diagnosis of non‐alcoholic fatty liver disease [PDF]

Alimentary Pharmacology & Therapeutics, 2011
no ...
Wlazlo, Nick, Van Greevenbroek, Marleen M. J, Ferreira, Isabel, Bravenboer, Bert, Stehouwer, Coen D   +4 more
openaire   +6 more sources

Statins and non‐alcoholic fatty liver disease [PDF]

Liver International, 2019
Dear Editor, In April 9 issue, van den Berg et al1 report interesting results on the indication for lipid‐lowering treatment in a large cohort with suspected non‐alcoholic fatty liver disease (NAFLD) within the population‐based Lifelines Cohort Study.
Angelico F, Baratta F, Pastori D, Del Ben M   +3 more
openaire   +2 more sources

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [PDF]

, 2011
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried.
C Clar, Henderson, R., Gurung, T., N Waugh, N Sattar, N Ghouri, Clar, C., Sattar, Naveed, Sattar, N., Fraser, A., T Gurung, Gurung, T. (Tara), D Shyangdan, A Fraser, Shyangdan, D., D Preiss, Waugh, Norman, Shyangdan, D. (Deepson), R Henderson, Ghouri, N., Preiss, D., Waugh, N.   +21 more
core   +1 more source